[company_age]5.0[/company_age][employees]11-50 employees[/employees][funding]Series B[/funding][description]VICO Therapeutics is a biotechnology company specializing in developing RNA modulating therapies for patients with severe, genetic neurological disorders. Their VICOMER platform designs antisense oligonucleotides for various genetic defects by modulating or editing RNA. VICO Therapeutics is committed to advancing RNA modulating therapies for patients with severe, genetic neurological disorders. VICO is initially targeting spinocerebellar ataxia types 3 and 1 and Huntington’s disease. Their VICOMER platform designs antisense oligonucleotides for various genetic defects by modulating or editing RNA. VICO Therapeutics is a leader in RNA modulation with antisense oligonucleotides focused on genetic neurological disorders. Their pipeline of programs includes VO659, currently being developed for multiple polyglutamine disorders, spinocerebellar ataxia type 3 and type 1 and Huntington’s disease. VO659 targets the CAG repeat expansion in an allele preferential manner, is reversible and transient in nature and does not change DNA code. The VICOMERTM antisense oligonucleotide platform offers multiple different mechanisms of action, enabling VICO Therapeutics to design RNA modulating therapeutics to address specific genetic defects at the source.[/description][ps]RNA modulating therapies for genetic neurological disorders.[/ps]